AUS
NZ
UK
CA
USA
IND
Healt
Biotech Momentum Rises on Lamington Day with Fresh Updates from ASX-Listed Companies
July 21, 2025 02:54 PM AEST| By Team Kalkine MediaHighlights,Lumos Diagnostics announces new US partnership,Cleo Diagnostics progresses toward FDA filing,PYC Therapeutics reports clinical trial milestones,On Lamington Day, a symbol of accidental brilliance in Australian culinary history, the biotech...
CSL (ASX:CSL) Shares Surge in Focus: Global Healthcare Growth & Allords Presence Driving Momentum
July 18, 2025 04:44 PM AEST| By Team Kalkine MediaHighlights,CSL’s diversified healthcare units span global markets,Stable revenue from essential services draws attention,Healthcare sector seen as a long-term structural growth theme,CSL (CSL), a prominent name in the biotechnology landscape, continu...
Why CSL (ASX:CSL) Remains a Resilient Force Among ASX200 Healthcare Stocks
July 18, 2025 03:50 PM AEST| By Team Kalkine MediaHighlights,CSL operates across critical segments of the healthcare industry,Healthcare companies benefit from resilient revenue streams,Ethical investing trends align with CSL’s long-term potential,CSL (ASX:CSL), a long-standing and reputable player...
ASX 200 Index: CSL Faces Uncertainty Amid Trump's Proposed Drug Tariffs
July 18, 2025 03:06 PM AEST| By Team Kalkine MediaHighlights,Proposed U.S. tariffs pose threat to key Australian biotech exports,CSL’s reliance on U.S. revenue could face margin strain,ASX healthcare sentiment may shift under geopolitical tension,The,ASX 200 Index,could be entering a period of turbu...
CSL (ASX:CSL) Faces Market Pressure Despite Earnings Growth | ASX Top 300 Focus
July 17, 2025 07:19 PM AEST| By Team Kalkine MediaHighlights,CSL share price trails behind market performance over one year,Revenue and earnings show positive movement despite stock dip,Dividend yield appears to have minimal impact on valuation,CSL Limited (CSL), a recognised name on the,ASX top 300...
Prescient Therapeutics Expands Global Trial Footprint for PTX-100
July 17, 2025 10:03 AM AEST| By Team Kalkine MediaHighlights,Prescient opens its first US trial site for PTX-100,Clinical trial expansion targets cutaneous T-cell lymphoma,Innovative GGT-1 blocker aims to meet urgent medical needs,Prescient Therapeutics (ASX:PTX) has confirmed the initiation of its...
Are Cochlear’s (ASX:COH) Shares Running Ahead of Fundamentals? A Closer Look Within the ASX200
July 17, 2025 10:02 AM AEST| By Team Kalkine MediaHighlights,Cochlear's,share valuation may reflect optimism beyond earnings growth.,Recent performance mirrors,broader,market, raising valuation questions.,Investor expectations may be outpacing realistic financial outlooks.,Cochlear (ASX:COH), a nota...
CSL (ASX:CSL) and Pro Medicus (ASX:PME): Healthcare Innovators Shaping the ASX 100 Landscape
July 16, 2025 08:28 PM AEST| By Team Kalkine MediaHighlights,CSL operates across plasma, vaccines, and nephrology care,Pro Medicus leads in radiology software and global healthcare IT,Both companies contribute to innovation in medical technology,Australia’s healthcare sector remains a vital pillar o...
ResMed (ASX:RMD): ASX 100 Healthcare Leader Signals Solid Growth in 2025
July 16, 2025 07:31 PM AEST| By Team Kalkine MediaHighlights,ResMed (RMD) maintains upward revenue and profit momentum,Healthy balance sheet supports long-term operational stability,SaaS integration strengthens out-of-hospital healthcare delivery,ResMed (RMD), a dual-listed medical technology compan...
Mesoblast (ASX:MSB) Insider Confidence Stands Out Amid ASX 300 Landscape
July 16, 2025 05:15 PM AEST| By Team Kalkine MediaHighlights,Insider transactions reflect long-term confidence,Substantial ownership by insiders in focus,ASX 300 biotech sees notable internal support,Mesoblast, a key player in the biotechnology space and part of the,ASX 300,, has recently attracted...
Imugene (ASX:IMU) Secures Capital to Accelerate Clinical Trials for Innovative CAR-T Therapy
July 16, 2025 05:07 PM AEST| By Team Kalkine MediaHighlights,Imugene advances azer-cel therapy for difficult lymphoma cases,Capital raised supports pivotal Phase 2 clinical trial,Positive early results boost development momentum,Imugene (ASX:IMU), a biotech company working on cutting-edge cancer imm...
Prescient Therapeutics (ASX:PTX) Begins US Enrolment for PTX-100 Trial | ASX 300
July 16, 2025 04:24 PM AEST| By Team Kalkine MediaHighlights,Prescient Therapeutics launches first US site at VCU Massey for Phase 2a PTX-100 trial,The global study now includes patients across both US and Australia,PTX-100, a GGT-1 inhibitor, is the only compound of its class currently in clinical...
Lumos Diagnostics (ASX:LDX) Secures Major US Deal for FebriDx® | All Ordinaries
July 16, 2025 04:21 PM AEST| By Team Kalkine MediaHighlights,Lumos Diagnostics signs exclusive multi-year US distribution deal with PHASE Scientific,Agreement includes milestone payments tied to regulatory progress for FebriDx®,CLIA waiver study nearing completion with submission expected in coming...
Tryptamine Therapeutics Expands Psilocin Clinical Team Ahead of TRP-8803 Trial | All Ordinaries
July 16, 2025 04:12 PM AEST| By Team Kalkine MediaHighlights,Tryptamine Therapeutics strengthens TRP-8803 program with two senior appointments,Australian-based team structure expected to enhance operational efficiency,Preparations underway for first-ever Binge Eating Disorder trial with Swinburne Un...
Tryptamine Therapeutics Advances Psychedelic Research with Key Appointments | ASX200 Clinical Innovation Update
July 16, 2025 01:59 PM AEST| By Team Kalkine MediaHighlights,Tryptamine Therapeutics expands its clinical team with top experts,Focus intensifies on innovative psilocin-based treatment development,Preparations underway for groundbreaking binge eating disorder trial,Tryptamine Therapeutics (ASX:TYP)...
Imugene Bolsters Clinical Trial Funding with Capital Raise | ASX200 Pipeline Progress
July 16, 2025 01:48 PM AEST| By Team Kalkine MediaHighlights,Imugene strengthens funding through placement and SPP,Focus remains on advancing the azer-cel clinical trial,Strategic financial planning supports long-term R&D efforts,Imugene (ASX:IMU), a clinical-stage immuno-oncology company, has taken...
Prescient Therapeutics Extends SPP Timeline | ASX 300 Biotech Eyes PTX-100 Progress
July 15, 2025 04:09 PM AEST| By Team Kalkine MediaHighlights,Prescient Therapeutics extends Share Purchase Plan deadline,Funds allocated to advance Phase 2 trial for oncology candidate PTX-100,Broader pipeline includes cell therapy enhancements and modular CAR-T platform,Prescient Therapeutics Ltd (...
Compumedics (ASX:CMP) Marks Major Turnaround with Robust Revenue Growth and Strategic Vision
July 15, 2025 11:39 AM AEST| By Team Kalkine MediaHighlights,Compumedics records robust growth across Sleep & Neurology segments,SaaS platforms show expanding global traction,Strategic focus aligned with,high-margin,recurring revenue model,Compumedics (ASX:CMP), a notable medical technology company,...
Compumedics Signals Strategic Growth Shift with Record Results: Momentum Builds Across SaaS and Sleep Diagnostics
July 15, 2025 10:12 AM AEST| By Team Kalkine MediaHighlights,Compumedics shifts into a new growth phase with innovation-led momentum,Sleep diagnostics and SaaS platforms,emerge,as key revenue drivers,Expansion in global neurotech markets supports long-term growth strategy,Compumedics (ASX:CMP) is st...
Imugene (ASX:IMU) Progresses Azer-cel Trial with Promising Data Amid ASX200 Landscape
July 14, 2025 11:43 AM AEST| By Team Kalkine MediaHighlights,Positive data drives Imugene’s expansion of trial scope,Azer-cel shows strong promise in relapsed lymphoma cases,Regulatory progress signals broader therapeutic potential,Imugene (ASX:IMU), a clinical-stage immuno-oncology company, has rep...
Advertise your brand on Kalkine Media